Novo Nordisk(US:NVO) 第一财经·2025-09-10 09:43Core Viewpoint - Novo Nordisk announced a significant restructuring plan involving the layoff of 9,000 employees, approximately 11.5% of its workforce, to streamline operations and enhance decision-making speed in response to competitive pressures in the diabetes and obesity markets [3][4]. Group 1: Restructuring and Financial Impact - The restructuring is expected to save the company 8 billion Danish kroner (approximately 1.26 billion USD) annually [3]. - A global hiring freeze has been implemented for non-critical positions [3]. - The company anticipates a one-time restructuring cost of 9 billion Danish kroner in Q3, with expected savings of 1 billion Danish kroner in Q4 [4]. Group 2: Market Competition and Challenges - Novo Nordisk's stock price has dropped nearly 60% over the past year, with a current market value of approximately 184 billion USD [4]. - The company faces increasing competition in the weight loss drug sector, particularly from Eli Lilly's newly approved weight loss medication, which has pressured Novo Nordisk's market share [5]. - In China, Novo Nordisk is not only competing with Eli Lilly but also with numerous local pharmaceutical companies, especially as the core patent for semaglutide is set to expire in 2026, leading to a wave of generic drug approvals [6]. Group 3: Future Outlook and Strategy - The company projects an operating profit growth rate of 4% to 10% for the year, down from a previous forecast of 10% to 16% due to restructuring costs [4]. - Novo Nordisk emphasizes the importance of innovation and effective resource allocation to adapt to market changes and maintain competitiveness [6].